Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

Inclusion Criteria:

* Age 18 years or older
* ECOG performance status (PS) 0-2
* Expected survival of at least 12 weeks
* CD20-positive marginal zone lymphoma confirmed according to WHO 2022 lymphoma classification standards, including the three subtypes: nodal MZL, extranodal MZL, and splenic MZL
* Measurable lesions by contrast-enhanced computed tomography/magnetic resonance imaging (CT/MRI)
* Meet the NCCN guideline criteria for MZL treatment and have not previously received systemic therapy for MZL (excluding hormone therapy and anti-infective treatment)
* Main organ function within normal limits, meeting the following criteria (excluding abnormalities caused by lymphoma):

  1. Hematology test standards:

     1. ANC ≥ 1.0 × 10\^9/L
     2. PLT ≥ 75 × 10\^9/L (for patients with confirmed bone marrow involvement: ≥ 50 × 10\^9/L)
     3. Hb ≥ 80 g/L
  2. Biochemistry test standards:

     1. TBIL \< 2 × ULN
     2. ALT and AST \< 2.5 × ULN (for patients with liver involvement, ALT and AST \< 5 × ULN)
     3. Endogenous creatinine clearance ≥ 40 ml/min (Cockcroft-Gault formula)
* Women of childbearing potential must use reliable contraception or have a negative pregnancy test (blood or urine) within 7 days prior to enrollment and agree to use appropriate contraception during the trial and for 8 weeks after the last dose of the study drug. For men, agreement to use appropriate contraception during the trial and for 8 weeks after the last dose of the study drug or previous surgical sterilization is required
* Subjects voluntarily agree to participate in this study, sign the informed consent form, have good compliance, and cooperate with follow-up

Exclusion Criteria:

* Patients with central nervous system involvement
* Patients with a history of or concurrent untreated malignant tumors, except for cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer
* Patients with the following cardiovascular diseases: myocardial ischemia or myocardial infarction of grade II or above, uncontrolled arrhythmias (including QTc interval ≥450 ms for men, ≥470 ms for women); heart failure of NYHA class III-IV, or left ventricular ejection fraction (LVEF) \<50% as indicated by cardiac ultrasonography; 4. Coagulation dysfunction (INR \>1.5 or prothrombin time (PT) \> ULN + 4 seconds, or APTT \>1.5 ULN), bleeding tendency, or currently receiving thrombolytic or anticoagulant therapy
* Arterial or venous thrombotic events occurring within 12 months prior to enrollment, such as cerebrovascular events (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, or pulmonary embolism
* Known genetic or acquired bleeding or thrombotic disorders (e.g., hemophilia, coagulation disorders)
* Major surgery or severe traumatic injury, fracture, or ulceration within 4 weeks prior to enrollment
* Factors significantly affecting oral drug absorption, such as dysphagia, chronic diarrhea, or intestinal obstruction
* Active infections requiring antimicrobial treatment (e.g., antibacterial or antiviral drugs, excluding chronic hepatitis B antiviral therapy or antifungal treatments); 10. Active hepatitis B (HBV DNA ≥2000 IU/mL or 104 copies/mL) or hepatitis C (HCV antibody positive and HCV RNA above the detection limit of the assay)
* History of substance abuse of psychiatric drugs that cannot be discontinued or mental disorders
* Participation in another anti-tumor drug clinical trial within 4 weeks prior to enrollment
* Treatment with strong CYP3A4 inhibitors within 7 days prior to enrollment, or treatment with strong CYP3A4 inducers within 12 days prior to enrollment
* Pregnant or breastfeeding women; patients of childbearing potential who are unwilling or unable to use effective contraception
* Other conditions that the investigator deems may affect the conduction of the clinical study or the assessment of study results